Physician profile
Karrah E Dattilo
NPI 1427519313
$1,123.93
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $92.57 · 2023: $154 · 2024: $580 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $223.32 | 2024-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $214.44 | 2023-2025 | |
| Abbvie INC. | $149.36 | 2023-2025 | |
| Boston Scientific Corporation | $114.33 | 2020-2024 | |
| Shield Therapeutics INC | $103.33 | 2024 | |
| Exeltis, USA INC. | $78.74 | 2024-2025 | Slynd |
| Sage Therapeutics, LLC | $54.44 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $51.56 | 2024 | Paragard T 380a |
| Pfizer INC. | $30.63 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.12 | 2025 | |
| Hydrofera LLC | $22.99 | 2025 | Sorbact Other |
| Millicent US INC | $20.69 | 2025 | Intrarosa, Femlyv |
| Organon LLC | $15.91 | 2024 | |
| Amgen INC. | $15.07 | 2023 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karrah Dattilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.